AnaptysBio Inc (ANAB):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C9781)
◆英語タイトル:AnaptysBio Inc (ANAB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9781
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:61
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
AnaptysBio Inc (AnaptysBio) is a clinical-stage biotechnology company that focuses on the development of antibody product candidates for the treatment of inflammatory, autoimmune and atopic diseases. The company develops its product candidates through its proprietary antibody discovery technology platform, somatic hypermutation (SHM). Its product candidates are being developed for the treatment of moderate-to-severe adult atopic dermatitis, food allergies and asthma, generalized pustular psoriasis and palmo-plantar pustular psoriasis and for the treatment of human autoimmune diseases. The company has partnership with AnaptysBio, TESARO and Celgene, to develop its product candidates. AnaptysBio is headquartered in San Diego, California, the US.

AnaptysBio Inc (ANAB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AnaptysBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AnaptysBio Inc, Medical Devices Deals, 2012 to YTD 2018 10
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
AnaptysBio Raises USD40 Million in Series D Financing 12
AnaptysBio Raises US$2 Million In Venture Financing 13
Partnerships 14
Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 14
AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 15
AnaptysBio Enters Into Co-Development Agreement With Novartis 16
AnaptysBio Enters Into Co-Development Agreement With A Pharma Company 17
Licensing Agreements 18
Tesaro Amends Licensing Agreement With AnaptysBio 18
Equity Offering 20
AnaptysBio Raises USD239 Million in Public Offering of Shares 20
AnaptysBio Prices USD205.5 Million in Public Offering of Shares 22
AnaptysBio Raises USD0.9 Million in Private Placement of Shares up on Exercise of Warrants 23
AnaptysBio Raises USD1.8 Million in Private Placement of Shares up on Exercise of Warrants 24
AnaptysBio Raises USD86.3 Million in IPO 25
Asset Transactions 27
Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 27
AnaptysBio Inc – Key Competitors 28
AnaptysBio Inc – Key Employees 29
AnaptysBio Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 07, 2018: AnaptysBio announces second quarter 2018 financial results and provides pipeline updates 31
May 08, 2018: AnaptysBio Announces First Quarter 2018 Financial Results and Provides Pipeline Updates 34
Mar 05, 2018: AnaptysBio Reports Fourth Quarter and Full Year 2017 Financial Results 36
Nov 07, 2017: AnaptysBio Announces Third Quarter 2017 Financial Results and Provides Pipeline Updates 38
Aug 10, 2017: AnaptysBio Announces Second Quarter 2017 Financial Results and Provides Pipeline Updates 40
May 11, 2017: AnaptysBio Announces First Quarter 2017 Financial Results and Provides Pipeline Update 41
Mar 08, 2017: AnaptysBio Announces 2016 Operating Results and Pipeline Progress 42
Corporate Communications 44
Aug 24, 2017: AnaptysBio Announces Appointment of J. Anthony Ware, M.D. to Board of Directors 44
Jan 11, 2017: AnaptysBio Announces The Appointment Of Dominic Piscitelli As Chief Financial Officer 45
Clinical Trials 46
May 29, 2018: AnaptysBio Presents Updated ANB019 Clinical Data at the 2018 EAACI Congress 46
May 29, 2018: AnaptysBio Presents Updated ANB020 Clinical Data at the 2018 EAACI Congress 47
May 01, 2018: AnaptysBio Announces ANB019 Clinical Data Presentation at the 2018 EAACI Congress 49
May 01, 2018: AnaptysBio Announces ANB020 Clinical Data Presentation at the 2018 EAACI Congress 50
Mar 26, 2018: AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients 51
Feb 17, 2018: AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting 53
Feb 07, 2018: AnaptysBio To Present Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting 54
Nov 06, 2017: AnaptysBio Reports Positive ANB019 Top-line Phase 1 Clinical Trial Results 55
Oct 10, 2017: AnaptysBio Reports Positive Topline Proof-of-Concept Data from Phase 2a Clinical Trial of ANB020 in Atopic Dermatitis 56
Apr 06, 2017: AnaptysBio Announces First-In-Human Dosing of ANB019 58
Mar 04, 2017: AnaptysBio Announces Data from Scientific Collaboration with the Benaroya Research Institute Presented at the AAAAI 2017 Annual Meeting 59
Feb 13, 2017: AnaptysBio to Present Data from ANB020 Program at Two Upcoming Medical Meetings 60
Appendix 61
Methodology 61
About GlobalData 61
Contact Us 61
Disclaimer 61

List of Tables
AnaptysBio Inc, Pharmaceuticals & Healthcare, Key Facts 2
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AnaptysBio Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AnaptysBio Inc, Deals By Therapy Area, 2012 to YTD 2018 9
AnaptysBio Inc, Medical Devices Deals, 2012 to YTD 2018 10
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
AnaptysBio Raises USD40 Million in Series D Financing 12
AnaptysBio Raises US$2 Million In Venture Financing 13
Momenta Pharma Enters into Co-Development Agreement with AnaptysBio for Antibody Discovery 14
AnaptysBio Enters Into Co-Development Agreement With Gilead Sciences For Antibody Discovery 15
AnaptysBio Enters Into Co-Development Agreement With Novartis 16
AnaptysBio Enters Into Co-Development Agreement With A Pharma Company 17
Tesaro Amends Licensing Agreement With AnaptysBio 18
AnaptysBio Raises USD239 Million in Public Offering of Shares 20
AnaptysBio Prices USD205.5 Million in Public Offering of Shares 22
AnaptysBio Raises USD0.9 Million in Private Placement of Shares up on Exercise of Warrants 23
AnaptysBio Raises USD1.8 Million in Private Placement of Shares up on Exercise of Warrants 24
AnaptysBio Raises USD86.3 Million in IPO 25
Momenta Pharma Exercises Option To Acquire Novel Antibodies Program from AnaptysBio 27
AnaptysBio Inc, Key Competitors 28
AnaptysBio Inc, Key Employees 29
AnaptysBio Inc, Subsidiaries 30

List of Figures
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
AnaptysBio Inc, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ AnaptysBio Inc (ANAB):製薬・医療:M&Aディール及び事業提携情報(AnaptysBio Inc (ANAB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆